美创医疗完成亿元级股权融资，强化医用植入级ePTFE产品研发注册

Core Viewpoint - Meichuang Medical has successfully completed a new round of financing amounting to over 200 million yuan, with several self-developed products already approved and beginning commercialization [1][3]. Group 1: Financing and Investment - Meichuang Medical announced the completion of a new round of equity financing, with contributions from multiple institutions including Suzhou Venture Capital and Tianfang Silicon Valley [1]. - In January of this year, Meichuang Medical completed an A+ round of financing exceeding 100 million yuan, with investors including Sequoia China and Yifeng Capital [1]. - The recent financing will strengthen Meichuang Medical's commercialization layout and support its core technology platform [3]. Group 2: Product Development and Market Position - Meichuang Medical has achieved production and mass production of medical-grade ePTFE materials, becoming the first Chinese manufacturer to overcome the "bottleneck" in this area [2]. - The company has completed the National Medical Products Administration (NMPA) documentation for ePTFE tubing and membranes, and is working with various medical device manufacturers to customize and replace ePTFE materials [2]. - Meichuang Medical is accelerating clinical trials and registrations for multiple self-developed products, with some already approved for commercialization, aiming to quickly enter the domestic peripheral vascular and tumor intervention medical market [3]. Group 3: Industry Outlook and Strategic Vision - The founder of Meichuang Medical emphasized the importance of technological innovation as the core driving force for the company, aiming to enhance product registration, clinical transformation, and manufacturing capabilities [3]. - Investors expressed confidence in the aging population's impact on vascular health investment opportunities, highlighting Meichuang Medical's competitive edge in the peripheral vascular sector through its self-developed ePTFE materials [3]. - The company is expected to leverage its unique development logic and solid resource accumulation to continue advancing its core products despite external uncertainties [3].